Fibro-Vein, 5 mg/ml 2 ml 5 pcs

The drug Fibro-Vein has a venosclerosing effect, it has surface-active properties.

Injection of the drug into the lumen of the varicose vein causes irritation of the vessel intima with subsequent fibrosis, adhesion of the vein walls and its obliteration.

It has no noticeable effect on the functions of the central and peripheral nervous system, cardiovascular system, renal and hepatic function, biochemical parameters of blood and urine.

In contact with perivascular tissues it has an irritating effect.

Indications

Treatment of uncomplicated, moderately pronounced varicose veins of the lower extremities by compression sclerotherapy. Treatment of telangiectasias.

Active ingredient

Composition

1 ml contains:

The active ingredient:

Sodium tetradecyl sulfate 5 mg.

Auxiliary substances:

benzyl alcohol,

sodium phosphate displaced,

Potassium phosphate disubstituted,

water for injection.

How to take, the dosage

Before a course of venosclerosing therapy, a trial injection of the drug should be performed to detect possible individual intolerance. In the patient standing, perpendicular to the skin surface a needle (without a syringe) is inserted into the most pronounced distal variceal nodule. As soon as blood begins to flow from the needle, the patient is laid on his back, and the limb is raised at an angle of 30-40 degrees. After insertion, the puncture site is pressed with a sterile gauze ball and the needle is removed.

The puncture site is covered with a dressing, and the leg, which remains elevated, is bandaged with an elastic bandage from the toes to the upper third of the thigh. To prevent possible damaging effect on endothelium of deep veins with their subsequent thrombosis, patients are recommended to walk vigorously for at least 2-3 hours immediately after injection. Fibro-Vein is injected into the distal parts of the blood-free varicose veins, followed by immediate and prolonged elastic compression.

The choice of the drug concentration depends on the diameter of the varicose vein to be treated. Fibro-Vein 3% solution is used for obliteration of large diameter varicose veins (1 cm and more), 1% is used for treatment of superficial varicose veins up to 1 cm in diameter. 0.5% and 0.2% solutions of the drug are used for injection sclerotherapy of intradermal varices and telangiectasia. In the presence of an extensive widespread varicose vein process, injections of the solution are repeated 2-10 times at intervals of 3-5 days.

Fibro-Vein 3%: Injected at the rate of 0.5-1.0 ml for each 10 cm of varicose vein. The maximum dose per treatment session is 4 ml and the recommended needle is 25 G x 5/8″.
Fibro-Vein 1%-0.5%: It is injected at the rate of 0.25-1.0 ml for each 5 cm of the varicose vein. Maximum dose per treatment session is 10 ml, recommended needle is 27 G x 1/2″, 30 G x 1/2″.
Fibro-Vein 0.2%: It is injected at the rate of 0.1-1.0 ml for each 3-5 cm of the intracutaneous varicose vein or telangiectasia. Maximum dose per treatment session is 10 ml, the recommended needle is 30 G x 1/2″.
In one therapy session the drug is injected into 2-6 points with 0.3-0.5 ml in each (preferably 1 ml).

If staged injection and sclerosing treatment is required, sclerosing of superficial veins is started from the lateral branches, and injection into the main venous trunk is performed last.
With combined treatment in combination with surgery – it is injected in varicose tributaries (after removal of superficial main trunks).

Interaction

It is not known. Pharmaceutically incompatible with heparin. It is not recommended to combine with oral contraceptives.

Special Instructions

1. Fibro-Vein should be used by physicians proficient in sclerotherapy techniques. Valvular insufficiency and deep vein condition must be properly evaluated.
2. Vein sclerosing is performed with caution if absolute certainty of patency of deep and communicating veins of the lower limbs.
3. Prior to treatment, the patient’s allergic history should be known. It is possible to administer 0.25-0.5 ml of Fibro-Vein to the patient 24 hours before the treatment to detect a possible allergic reaction.
4. Caution should be exercised when treating patients with peripheral atherosclerosis, Buerger’s disease.
5. The drug should be administered especially carefully in the area above and behind the medial ankle because the posterior tibial artery is located there.
6. Avoid extravasal (para-venous) and intra-arterial administration.
7. The drug should not be used in case of precipitation or color change of the solution.
8. Precipitate may form in solution when the temperature decreases and dissolves when heated.

Contraindications

Side effects

Dizziness, headache, nausea and increased sweating may occur during the administration of the drug, especially during the first treatment session.

A burning sensation and slight soreness at the injection site are noted when the drug is injected.

In case of contact of the drug with the skin, hyperpigmentation, infiltration and skin necrosis may develop.

Allergic reactions (urticaria, rash, anaphylactic shock) are rare.

Local reactions: intravarice hematoma at the injection site, ascending phlebitis with or without associated periphlebitis.

Systemic reactions: bronchospasm, fever, pulmonary vein thrombosis.

In case of accidental intraarterial injection – obliteration of the adherent vessel (up to the need for limb amputation), embolism (even 4 months after the procedure); with paravenous – development of soft tissue necrosis.